Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Amylyx Pharmaceuticals, Inc.

AMLX · Nasdaq · CIK 0001658551 · Healthcare · Drug Manufacturers—Specialty & Generic

INSIDER SIGNAL

No active buy signal

1 qualifying P purchase group
in the current 180-day scoring window

21 Form 4 transaction lines observed in the same window
13 sales · 7 option, withholding, award, gift or other lines

Last qualifying purchase2026-05-21 · Firestone Karen · $51.3K

WHY NO ACTIVE SIGNAL?

Purchase activityPresent
Recent buying1 qualifying line group(s)
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Mazzariello GinaChief Legal Officer
▼▼○▼
Klee Justin B.Co-Chief Executive Officer
○▼
FRATES JAMES MChief Financial Officer
○▼
Cohen Joshua BCo-Chief Executive Officer
○▼
Bedrosian Camille LChief Medical Officer
○▼
Firestone KarenDirector
●○
● Purchase▼ Sale○ Other

Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Firestone Karen · $51.3K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-21–2026-05-21

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-05-21 · Firestone Karen.

Recent Form 4 activity

2Purchases
31Sales
17Other Form 4 lines
37SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING13 sale line(s) · context only
OTHER7 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-19.4%
3M
+54.6%
6M
+85.9%
12M
—

Volatility & liquidity

Volatility
87.7%
Beta
-0.12
Avg daily value
USD 64.4M

Valuation

Market cap
USD 3.5B
P/E
—

Fundamentals

Profit margin
0.0%
ROE
-47.4%
Industry
Drug Manufacturers—Specialty & Generic

Market data

Price data up to: 2026-10-03 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · From Yahoo Finance: Market cap, Profit margin · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
12,666,971
Previous report
13,512,753
Avg daily volume
1,382,131
Days to cover
9.2

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-21Firestone KarenPurchase (P)Common Stock3,800USD 13.51USD 51,338SEC filing ↗
2025-12-23Firestone KarenPurchase (P)Common Stock8,100USD 12.45USD 100,845SEC filing ↗
2025-03-20Zeiher Bernhardt GPurchase (P)Common Stock10,000USD 3.70USD 37,000SEC filing ↗
2024-09-12FRATES JAMES MPurchase (P)Common Stock40,000USD 2.53USD 101,200SEC filing ↗
2024-09-05Firestone KarenPurchase (P)Common Stock50,000USD 2.13USD 106,500SEC filing ↗
2024-09-03MILNE GEORGE M JRPurchase (P)Common Stock100,000USD 2.20USD 220,000SEC filing ↗
2024-05-15Quimi DaphnePurchase (P)Common Stock2,250USD 1.89USD 4,252SEC filing ↗
2024-05-14Quimi DaphnePurchase (P)Common Stock2,750USD 1.89USD 5,198SEC filing ↗
2023-12-15Firestone KarenPurchase (P)Common Stock4,000USD 14.97USD 59,880SEC filing ↗
2023-03-16Firestone KarenPurchase (P)Common Stock1,000USD 31.99USD 31,990SEC filing ↗
2022-01-11MVIL, LLC; Morningside Venture Investments LtdPurchase (P)Common Stock263,158USD 19.00USD 5,000,002SEC filing ↗
2022-01-11Morningside Venture Investments LtdPurchase (P)Common Stock263,158USD 19.00USD 5,000,002SEC filing ↗
2022-01-11HALVORSEN OLE ANDREAS; Ott David C.; Shabet Rose Sharon; VIKING GLOBAL INVESTORS LP; Viking Global Opportunities GP LLC; Viking Global Opportunities Illiquid Investments Sub-Master LP; Viking Global Opportunities Parent GP LLC; Viking Global Opportunities Portfolio GP LLCPurchase (P)Common Stock2,300,000USD 19.00USD 43,700,000SEC filing ↗
2022-01-06Olinger MargaretPurchase (P)Common Stock6,842USD 19.00USD 129,998SEC filing ↗
2022-01-06MILNE GEORGE M JRPurchase (P)Common Stock26,315USD 19.00USD 499,985SEC filing ↗

Form 4 evidence

50 transaction lines in the latest 365-day window; 247 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-05MILNE GEORGE M JRSale (S)Common Stock30,000USD 27.70USD 830,904SEC filing ↗
2026-09-10Mazzariello GinaSale (S)Common Stock9,536USD 32.46USD 309,548SEC filing ↗
2026-09-10Klee Justin B.Sale (S)Common Stock30,464USD 32.18USD 980,290SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-05MILNE GEORGE M JRSale (S)Common Stock30,000USD 27.70USD 830,904SEC filing ↗
2026-09-10Mazzariello GinaSale (S)Common Stock9,536USD 32.46USD 309,548SEC filing ↗
2026-09-10Klee Justin B.Sale (S)Common Stock30,464USD 32.18USD 980,290SEC filing ↗
2026-09-10FRATES JAMES MSale (S)Common Stock10,810USD 32.36USD 349,839SEC filing ↗
2026-09-10Cohen Joshua BSale (S)Common Stock30,464USD 32.19USD 980,632SEC filing ↗
2026-09-10Bedrosian Camille LSale (S)Common Stock10,028USD 32.39USD 324,833SEC filing ↗
2026-08-31Firestone KarenOption exercise / conversion (M)Common Stock50,000USD 3.40USD 170,250SEC filing ↗
2026-08-18Mazzariello GinaAward / grant (A)Common Stock21,284USD 0.00USD 0SEC filing ↗
2026-08-18Klee Justin B.Award / grant (A)Common Stock60,039USD 0.00USD 0SEC filing ↗
2026-08-18FRATES JAMES MAward / grant (A)Common Stock22,807USD 0.00USD 0SEC filing ↗
2026-08-18Cohen Joshua BAward / grant (A)Common Stock60,039USD 0.00USD 0SEC filing ↗
2026-08-18Bedrosian Camille LAward / grant (A)Common Stock22,807USD 0.00USD 0SEC filing ↗
2026-07-10Mazzariello GinaSale (S)Common Stock15,000USD 17.61USD 264,150SEC filing ↗
2026-07-09Mazzariello GinaSale (S)Common Stock15,000USD 18.32USD 274,800SEC filing ↗
2026-05-21Firestone KarenPurchase (P)Common Stock3,800USD 13.51USD 51,338SEC filing ↗
2026-03-05Mazzariello GinaAward / grant (A)Common Stock74,660USD 0.00USD 0SEC filing ↗
2026-03-05Klee Justin B.Award / grant (A)Common Stock248,865USD 0.00USD 0SEC filing ↗
2026-03-05FRATES JAMES MAward / grant (A)Common Stock95,990USD 0.00USD 0SEC filing ↗
2026-03-05Cohen Joshua BAward / grant (A)Common Stock248,865USD 0.00USD 0SEC filing ↗
2026-03-05Bedrosian Camille LAward / grant (A)Common Stock95,990USD 0.00USD 0SEC filing ↗
2026-03-02Mazzariello GinaSale (S)Common Stock6,844USD 14.52USD 99,375SEC filing ↗
2026-03-02Klee Justin B.Sale (S)Common Stock29,282USD 14.47USD 423,711SEC filing ↗
2026-03-02FRATES JAMES MSale (S)Common Stock7,909USD 14.52USD 114,839SEC filing ↗
2026-03-02Cohen Joshua BSale (S)Common Stock29,282USD 14.48USD 424,003SEC filing ↗
2026-03-02Bedrosian Camille LSale (S)Common Stock6,461USD 14.58USD 94,201SEC filing ↗
2026-02-23Mazzariello GinaSale (S)Common Stock3,419USD 14.14USD 48,345SEC filing ↗
2026-02-02Mazzariello GinaSale (S)Common Stock3,448USD 14.65USD 50,513SEC filing ↗
2026-02-02Klee Justin B.Sale (S)Common Stock15,500USD 14.69USD 227,695SEC filing ↗
2026-02-02FRATES JAMES MSale (S)Common Stock3,557USD 14.65USD 52,110SEC filing ↗
2026-02-02Cohen Joshua BSale (S)Common Stock15,500USD 14.68USD 227,540SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAMLX
CIK0001658551
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history247 transaction lines from 2022-01-06 to 2026-10-05
17 P purchase lines · 137 S sale lines · 93 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.